Meet GIA®: Your Digital Human® Screening Partner

Subtle changes can signal big problems, and the **Generative Intelligence Architecture** of GIA™ is designed to detect them. GIA™ screens patients in post-acute and long-term care, identifying subtle indicators of conditions that often go undetected. This helps clinicians focus their time and resources where they are needed most. GIA™ uses a vast dataset of 12.3M longitudinal patient records containing 27B clinical events to inform her screening process. She speaks 92 languages, ensuring patient comfort and understanding, and EHR systems like Cerner, Epic, and PointClickCare. The aim is to supplement, not replace, the expertise of medical professionals, providing another layer of insight for better patient care. By analyzing over 2,500 speech biomarkers and 436 visual data points within a five-minute conversation, GIA™ offers a detailed **clinical screening** for conditions like depression, anxiety, and PTSD. These results are then reviewed and approved by a clinician, ensuring responsible and effective use of this technology. Consider GIA™ as your partner in **clinical screening**.

How Does GIA®'s **Generative Intelligence Architecture** Differ From Other AI Tools?

GIA™’s **Generative Intelligence Architecture** is designed specifically for clinical screening in the complex environment of post-acute and long-term care. Unlike general-purpose AI, which has not yet demonstrated strong clinical results, GIA™ is built on a foundation of 12.3M longitudinal patient records and 27B clinical events. This allows her to identify patterns and nuances often missed by traditional methods. GIA™ synthesizes information from multiple sources, including speech biomarkers, visual cues, and patient responses, to create a risk profile for 46 different conditions (24 live, 22 in clinical validation). This multimodal approach, combined with a focus on conditions prevalent in PAC/LTC settings, sets GIA™ apart from other AI tools. She is bundled on Samsung Health Grade Galaxy devices, protected by Samsung Knox, and integrates with major EHRs, supporting a streamlined clinical experience. The accuracy of screening results, such as 81.6% for depression and an AUC of 0.97 for Parkinson's, has been clinically validated. Remember that a clinician always reviews and approves all screening results. GIA™ is powered by digitalhumanOS™.

What Clinical Conditions Can GIA® Effectively Screen For?

GIA™ screens for a spectrum of conditions prevalent in post-acute and long-term care. Her current screening capabilities include 24 conditions, with another 22 in clinical validation. These include depression, as well as Parkinson's disease. GIA™ also screens for risk factors related to falls, malnutrition, and **cognitive decline**. The breadth of screening allows for a more complete understanding of a resident’s health status. Early and accurate screening is critical. It allows for timely interventions that may prevent hospitalizations and improve quality of life. Keep in mind that a clinician always reviews and approves all screening results from GIA™. She is a **Digital Human**®, not a diagnostic tool. Her role is to provide insights that supplement clinical judgment.

How does GIA integrate into existing clinical operations?

GIA™ is designed to integrate into established clinical operations, not to disrupt them. She is bundled on Samsung Health Grade Galaxy devices, protected by Samsung Knox, and speaks 92 languages to improve patient comfort and engagement. She interfaces directly with major EHR systems like PointClickCare, Epic, Cerner, MatrixCare, Netsmart, and American HealthTech. This direct integration allows for data transfer and reduces the burden of manual data entry. Screening with GIA™ takes 40 seconds, and results are available in under 2 minutes. This speed and efficiency allow for more frequent screening, leading to quicker detection of potential issues. The clinical team reviews and approves all screening results. This helps to ensure that GIA™'s insights are considered in the context of the patient's overall health and history. The goal is to provide clinicians with more data, faster, so they can make better-informed decisions. GIA™ is a **Digital Human** powered by **Generative Intelligence Architecture**.

What regulatory considerations apply to using GIA?

Scienza Health understands the importance of regulatory compliance in healthcare. GIA is FDA-registered as a medical device establishment and fully HIPAA compliant. This offers reassurance that patient data is handled securely and responsibly. It is important to remember that GIA screens; she does not diagnose, treat, or prescribe. A clinician must always review and approve the results of any screening performed by GIA. We are committed to transparency and responsible AI deployment. Scienza Health provides comprehensive documentation and support to help facilities properly implement and oversee the use of GIA. We partner with facilities to ensure that GIA augments, not supplants, the vital role of clinicians in patient care. Our focus is on improving patient outcomes through responsible use of clinical AI.

Conclusion

GIA represents a new approach to **clinical screening**, providing clinicians with rapid, data-driven insights to improve patient care in **post-acute care** and long-term care settings. Her **generative intelligence architecture** offers a scalable and efficient way to detect conditions that might otherwise go unnoticed, but the human element of a clinician remains central to the process. Given the potential to improve resident well-being and reduce hospitalizations, how might GIA best augment your current clinical screening process?